

## Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the Menopause Strategies: Finding Lasting Answers for Symptoms and Health Research Network

Hadine Joffe, MD, MSc,<sup>1</sup> Katherine A. Guthrie, PhD,<sup>2</sup> Joseph Larson, MS,<sup>2</sup> Lee S. Cohen, MD,<sup>1</sup> Janet S. Carpenter, PhD, RN, FAAN,<sup>3</sup> Andrea Z. LaCroix, PhD,<sup>2</sup> and Ellen W. Freeman, PhD<sup>4</sup>

### Abstract

**Objective:** Vasomotor symptoms (VMS) recur after discontinuation of hormonal therapy. Selective serotonin reuptake inhibitors (SSRIs) are used increasingly to treat VMS, but whether VMS recur after cessation of SSRI is unknown. We hypothesized that relapse of VMS to baseline levels after SSRI cessation would be common and predicted by menopausal and psychological characteristics.

**Methods:** Recurrence of VMS (frequency, severity, and bother) was measured with daily diaries for 3 weeks after cessation of escitalopram, which was administered to perimenopausal/postmenopausal women with hot flashes and night sweats in an 8-week randomized, placebo-controlled trial. Blinding of staff and participants was maintained throughout. Relapse was defined as mean daily VMS frequency, severity, or bother 20% or less lower than pretreatment levels.

**Results:** Of 76, 57, and 51 women included in the analysis for VMS frequency, severity, and bother, 34.2%, 38.6%, and 37.3%, respectively, had relapse of VMS frequency, severity, and bother. In adjusted models, VMS frequency relapse was predicted by higher levels of pretreatment insomnia symptoms ( $P = 0.02$ ) and a weaker response to escitalopram ( $P = 0.03$ ).

**Conclusions:** Among women whose VMS improved with escitalopram, approximately one third relapsed swiftly after discontinuation of the medication. Those with pretreatment insomnia and those with a weaker response to escitalopram may be at greatest risk for VMS relapse after treatment discontinuation. Women should be educated about the likelihood of VMS symptom relapse when they discontinue SSRIs after receiving benefits from short-term treatment.

**Key Words:** Hot flash – Vasomotor symptoms – Selective serotonin reuptake inhibitor – Escitalopram – Randomized trial – Recurrence – Relapse.

Selective serotonin reuptake inhibitors (SSRIs) are effective and being increasingly used in treatments of vasomotor symptoms (VMS). Randomized placebo-controlled trials demonstrating the efficacy of SSRI for the treatment of VMS have shown benefits within 4 weeks of treatment.<sup>1</sup> However, the required duration of treatment to

maintain control of VMS is unknown, and little data are available to guide women about the likelihood that VMS will recur after cessation of SSRI.

In an 8-week double-blind, randomized, placebo-controlled trial, we recently showed that escitalopram 10 to 20 mg/day is more effective than placebo at reducing the frequency, severity,

Received May 30, 2012; revised and accepted August 2, 2012.

From the <sup>1</sup>Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA; <sup>2</sup>Fred Hutchinson Cancer Research Center, Seattle, WA; <sup>3</sup>School of Nursing, Indiana University, Indianapolis, IN; and <sup>4</sup>Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA.

**Funding/support:** This study was supported by a cooperative agreement issued by the National Institute on Aging, in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Development, the National Center for Complementary and Alternative Medicine, and the Office of Research and Women's Health, and by grants U01 AG032656, U01AG032659, U01AG032669, U01AG032682, U01AG032699, and U01AG032700 from the National Institute on Aging. At the Indiana University site, the project was funded in part with support from the Indiana Clinical and Translational Sciences Institute, funded in part by grant UL1 RR025761 from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award. Escitalo-

pram and matching placebo pills were provided by Forest Research Institute.

**Financial disclosure/conflicts of interest:** Dr. Joffe serves on the board of Noven Pharmaceuticals Inc., is an unpaid consultant to Sunovion Pharmaceuticals, and has received a research grant from Cephalon Inc. Dr. Cohen consults for Noven Pharmaceutical and PamLab LLC and has received grants from Forest Laboratories Inc., Ortho-McNeil Janssen, Pfizer Inc., Astra-Zeneca Pharmaceuticals, Bristol-Myers and Squibb, Cephalon Inc., GlaxoSmithKline, and Sunovion Pharmaceuticals Inc. Dr. LaCroix is a board member of the Center for Outcomes Research at the University of Massachusetts and the Amgen Scientific Methodology Advisory Committee for Profile. She is also a consultant for the Pfizer Mammographic Breast Density Advisory Meeting. Dr. Freeman has received research grants from Forest Laboratories Inc. and Bionovo.

**Address correspondence to:** Hadine Joffe, MD, MSc, Center for Women's Mental Health, Department of Psychiatry, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114. E-mail: hjoffe@partners.org

and bother of hot flashes and night sweats, whereas modest effects of placebo were also observed.<sup>2</sup> However, by 3 weeks after treatment cessation, the number of VMS per day had increased significantly in the escitalopram-treated group such that the frequency of VMS in those who had discontinued escitalopram approximated that of the group that had stopped placebo.<sup>2</sup> Consistent with recurrence of VMS frequency, VMS severity and bother also worsened, suggesting that improvements in the frequency, severity, and bother of VMS were lost rapidly when the SSRI was discontinued.<sup>2</sup>

Several studies have shown that VMS recur after discontinuation of hormone therapy (HT).<sup>3-6</sup> In observational studies of women who were receiving HT for VMS, 37% to 87% reported that they experienced VMS again when assessed several months to years after they had stopped HT.<sup>3,4</sup> Return of VMS occurs rapidly, within the first few weeks after HT cessation.<sup>4</sup> In a follow-up survey conducted 8 to 12 months after HT discontinuation, VMS had recurred in more than half of women aged 55 to 59 years who had VMS before combined estrogen-progestogen therapy and whose VMS were suppressed on estrogen-progestogen therapy.<sup>5</sup> Taken together, these data suggest that HT is not a curative therapy for VMS but rather that VMS are suppressed for the duration of the treatment period.

Although the occurrence of VMS after the cessation of HT and the SSRI escitalopram seems to be common, it is not known whether VMS are experienced at the same frequency or intensity after treatment discontinuation as was experienced before treatment was started (ie, whether symptoms are, in general, less frequent or less bothersome, or whether women tend to experience a “relapse” of their symptoms), with VMS recurring at a similar level as before initiation of VMS treatment. Consequently, we examined whether women who received escitalopram for treatment of VMS experienced a relapse of their symptoms within a 3-week period after escitalopram was discontinued in our randomized clinical trial. We hypothesized that VMS relapse would occur commonly within the short period after treatment cessation and that baseline menopausal and psychological characteristics would predict the likelihood of VMS recurrence.

## METHODS

Participants in this study were women enrolled in the clinical trial who improved 20% or more from their baseline symptom level in the frequency, severity, and bother of VMS after 8 weeks of escitalopram treatment. This subgroup of women was selected because they responded at least partially to the treatment and they represent the relevant clinical population for VMS treatment and its discontinuation.

The parent study was an 8-week multisite, randomized, placebo-controlled, double-blind trial of escitalopram 10 to 20 mg/day conducted within the Menopause Strategies: Finding Lasting Answers for Symptoms and Health Research Network. Details describing the study population and study procedures are available elsewhere.<sup>2</sup> Briefly, participants

were 204 perimenopausal, postmenopausal, or hysterectomized women aged 40 to 62 years who had a minimum of 28 bothersome or severe hot flashes or night sweats per week during a 3-week screening period. Participants were healthy women without clinical depression who were not taking any hormonal treatments, SSRI/serotonin-norepinephrine reuptake inhibitor (SNRI), tamoxifen, aromatase inhibitors, or VMS treatments.

Participants were randomly assigned to receive escitalopram 10 mg/day or matching placebo for the first 4 weeks of the study. Treatment assignment was stratified on race (white, African American, or others). After 4 weeks of treatment, the dose was increased to escitalopram 20 mg/day or matching placebo (2 pills/d in each treatment group) for the remaining 4 weeks of the trial if a participant had not experienced at least a 50% reduction in VMS frequency or VMS severity on a daily VMS diary. Those whose symptoms had responded by 50% or more after 4 weeks of treatment continued on escitalopram 10 mg/day or matching placebo for the remaining 4 weeks of the trial. All participants provided a written informed consent form, and the study was approved by the Institutional Review Board at each participating Menopause Strategies: Finding Lasting Answers for Symptoms and Health site.

## Measurement of VMS frequency, severity, and bother

A hot flash diary was completed daily through the entire trial and posttreatment period. The frequency, severity, and bother of hot flashes and night sweats were recorded at the end of the day to describe daytime symptoms and upon awakening for nighttime symptoms. Our outcomes were 7-day means of hot flash frequency, severity (0, none; 1, mild; 2, moderate; 3, severe), and bother (0, none; 1, a little; 2, moderate; 3, a lot).

## Posttreatment phase

The double blind was not broken during the posttreatment phase, and participants and staff remained unaware of which treatment had been received. For women who received escitalopram 10 mg/day, treatment was stopped at the conclusion of the 8-week trial. Those on escitalopram 20 mg/day took a total of three additional pills of escitalopram 10 mg/day every other day during the first posttreatment week. For the remainder of the 3-week period, participants took no study medication.

At the end of the 3-week period, posttreatment VMS diaries were collected together with the abbreviated Discontinuation-Emergent Signs and Symptoms Scale, which was used to assess 17 common SSRI withdrawal symptoms (anxious/nervous, irritable, crying or tearfulness, agitation, difficulty concentrating or paying attention, mood swings, insomnia, unusual and/or vivid dreams, excessive sweating, muscle tension, muscle aches, fatigue or tiredness, headaches, dizziness or lightheadedness, chills, nausea, or diarrhea).<sup>7</sup> Participants indicate whether each symptom is new, old but more severe, old but at the same intensity level, old but less severe, or not present. For

**TABLE 1.** Demographic and clinical characteristics of escitalopram-treated participants who had a higher than 20% reduction in hot flash frequency, severity, or bother during the 8-week trial

Participant characteristics	Frequency (n = 76)	Severity (n = 57)	Bother (n = 51)
Age at screening, mean (SD), y	53.74 (4.30)	52.96 (3.95)	52.65 (4.04)
Race, n (%)			
White	46 (60.5)	31 (54.4)	26 (51.0)
African American	27 (35.5)	23 (40.4)	22 (43.1)
Other	3 (3.9)	3 (5.3)	3 (5.9)
Marital status, n (%)			
Never married	12 (15.8)	11 (19.3)	10 (19.6)
Divorced/separated	10 (13.2)	5 (8.8)	4 (7.8)
Widowed	3 (3.9)	3 (5.3)	3 (5.9)
Married/marriage-like relationship	51 (67.1)	38 (66.7)	34 (66.7)
Education, n (%)			
High school diploma or GED, or less	13 (17.1)	9 (15.8)	8 (15.7)
School/training after high school	29 (38.2)	19 (33.3)	17 (33.3)
College graduate	34 (44.7)	29 (50.9)	26 (51.0)
Body mass index, n (%), kg/m <sup>2</sup>			
<25	26 (34.2)	20 (35.1)	19 (37.3)
25 to <30	23 (30.3)	17 (29.8)	14 (27.5)
≥30	27 (35.5)	20 (35.1)	18 (35.3)
Smoking, n (%)			
Never	41 (53.9)	29 (50.9)	27 (52.9)
Past	22 (28.9)	17 (29.8)	15 (29.4)
Current	13 (17.1)	11 (19.3)	9 (17.6)
Menopause status, n (%)			
Postmenopause	51 (67.1)	38 (66.7)	31 (60.8)
Perimenopause	17 (22.4)	13 (22.8)	14 (27.5)
Hysterectomy/unknown	8 (10.5)	6 (10.5)	6 (11.8)
Years since the final menstrual period, n (%)			
Unknown <sup>a</sup>	18 (23.7)	14 (24.6)	14 (27.5)
<1	19 (25.0)	14 (24.6)	15 (29.4)
1 to <3	19 (25.0)	16 (28.1)	12 (23.5)
≥3	19 (25.0)	12 (21.1)	9 (17.6)
Years of hot flashes, n (%)			
0-2	23 (30.3)	22 (38.6)	21 (41.2)
3-5	25 (32.9)	16 (28.1)	15 (29.4)
≥6	27 (35.5)	18 (31.6)	14 (27.5)
Hormone therapy use (ever), n (%)			
No	52 (68.4)	42 (73.7)	37 (72.5)
Yes	24 (31.6)	15 (26.3)	14 (27.5)
Insomnia Severity Index score, n (%)			
≤7	24 (31.6)	21 (36.8)	18 (35.3)
8-14	30 (39.5)	18 (31.6)	18 (35.3)
>14	21 (27.6)	17 (29.8)	14 (27.5)
Nine-item Patient Health Questionnaire depression score, n (%)			
No depression symptoms (0-4)	58 (76.3)	42 (73.7)	38 (74.5)
Depression symptoms (5-13)	18 (23.7)	15 (26.3)	13 (25.5)
Seven-item Generalized Anxiety Disorder score, n (%)			
No anxiety symptoms (0-4)	62 (81.6)	44 (77.2)	39 (76.5)
Anxiety symptoms (5-9)	14 (18.4)	13 (22.8)	12 (23.5)
Average daily hot flash frequency at screening, mean (SD)	9.30 (4.39)	9.00 (4.38)	9.18 (4.51)
<6	17 (22.4)	13 (22.8)	10 (19.6)
6 to <9	26 (34.2)	20 (35.1)	20 (39.2)
9 to <12	17 (22.4)	15 (26.3)	12 (23.5)
≥12	16 (21.1)	9 (15.8)	9 (17.6)
Average hot flash severity at screening, n (%) <sup>b</sup>			
Predominantly mild/moderate	28 (36.8)	21 (36.8)	18 (35.3)
Predominantly severe	48 (63.2)	36 (63.2)	33 (64.7)
Average hot flash bother at screening, n (%) <sup>c</sup>			
Predominantly a little/moderate	30 (39.5)	21 (36.8)	18 (35.3)
Predominantly a lot of bother	46 (60.5)	36 (63.2)	33 (64.7)
Escitalopram dose escalated on week 4, n (%)			
Yes	39 (51.3)	27 (47.4)	24 (47.1)
No	34 (44.7)	28 (49.1)	26 (51.0)

**TABLE 1.** (Continued)

Participant characteristics	Frequency (n = 76)	Severity (n = 57)	Bother (n = 51)
Hot flash reduction on week 8 higher than 50%, n (%)			
Yes	49 (64.5)	45 (78.9)	27 (52.9)
No	27 (35.5)	12 (21.1)	24 (47.1)

<sup>a</sup>Hysterectomy and/or oophorectomy.

<sup>b</sup>Predominantly mild/moderate is defined as an average weekly severity score of 2 or lower. Predominantly severe is defined as an average weekly severity score higher than 2.

<sup>c</sup>Predominantly a little/moderate is defined as an average weekly bother score of 3 or lower. Predominantly a lot is defined as an average weekly severity score higher than 3.

this analysis, a symptom was considered a withdrawal symptom if it was reported as new or old but more severe.

### Predictors of VMS relapse

The a priori characteristics of interest examined as potential predictors of hot flash relapse were as follows: age; race (white vs African American); baseline levels of hot flash frequency, severity, and bother; menopause status (postmenopausal vs perimenopausal); smoking status; body mass index; number of years since the final menstrual period (categorized as <1, 1 to <3, and 3 or more years); duration of hot flashes (categorized as 0-2, 3-5, and 6 or more years); prior HT use; final dose of escitalopram (20 vs 10 mg/d); and level of response to escitalopram therapy (≥50% vs 20%-49.9% reduction in VMS frequency, severity, or bother). Other menopause-related and psychological characteristics examined were baseline levels of insomnia symptoms on the Insomnia Severity Index (ISI),<sup>8</sup> depressive symptoms on the nine-item Patient Health Questionnaire,<sup>9</sup> and anxiety symptoms on the seven-item Generalized Anxiety Disorder.<sup>10</sup>

### Statistical methods

The primary outcome was relapse in hot flash frequency. This was defined as a difference of 20% or less in the frequency of hot flashes at 3 weeks after treatment cessation (week 11) compared with the pretreatment baseline. For example, a woman with 10 VMS at baseline who had 8.1 or more VMS 3 weeks after treatment cessation was considered to have had VMS frequency relapse. This definition of relapse was selected to identify those who no longer showed any benefit from the SSRI. All participants randomized to escitalopram who completed week 11 hot flash diaries were included in the analysis, unless their symptoms did not improve by at least 20% during the 8-week trial. Analyses of VMS severity and bother relapse were conducted using the same approach, with relapse defined similarly (ie, a difference of 20% or less in the reports on week 11 relative to the pretreatment baseline).

Logistic regression models were used to estimate the relationships between VMS relapse and covariates of interest. Variables with univariate *P* values of <0.05 were included in a multivariable analysis, along with baseline hot flash frequency. This logistic modeling process was repeated for the VMS severity and bother recurrence outcomes, adjusting

for the corresponding baseline VMS measure. Associations between VMS relapse and pretreatment insomnia symptoms (ISI score >7 vs ≤7 to indicate the presence of at least mild insomnia)<sup>8</sup> were further explored using Fisher's exact tests for small cells. The statistical significance of associations between VMS relapse and SSRI withdrawal symptoms was examined using  $\chi^2$  tests.

Analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC), with two-sided *P* values of <0.05 considered statistically significant. Secondary analyses are considered exploratory and should be interpreted with caution.


**RESULTS**

Of 205 women who entered the parent trial, 104 were randomly assigned to escitalopram. Of those, 97 (93.3%) completed the 8-week trial, and 93 (89.4%) completed the posttreatment phase of the trial. Among those who completed the posttreatment phase of the trial, 76 (81.7%) improved with escitalopram (defined as a ≥20% reduction in VMS frequency from baseline to the end of the 8-week treatment period) and were included in this analysis. Analyses of relapse in VMS severity and bother were conducted on 57 (61.3%) and 51 (54.8%) women, respectively, who had improved by at least 20% on these dimensions in the 8-week treatment trial.

The characteristics of the study participants in this analysis (Table 1) were similar in each of the three outcome groups (frequency, severity, and bother). The mean (SD) age was 53.7 (4.3) years; two thirds were postmenopausal, and the remaining were perimenopausal or had undergone hysterectomy. At baseline, the mean (SD) number of VMS was 10.0 (6.5) per day, and approximately two thirds rated their average daily VMS severity and average daily VMS bother as predominantly severe. Before treatment randomization, 40% of participants had mild insomnia symptoms, and 28% had moderate to severe insomnia symptoms. The dose of escitalopram was increased to 20 mg/day in 51.3% of the VMS frequency analysis sample, and 64.5% had at least a 50% reduction in VMS frequency during the 8-week escitalopram trial.

**VMS frequency, severity, and bother relapse**

Three weeks after cessation of escitalopram, 26 (34.2%) women met relapse criteria for VMS frequency, whereas 22 (38.6%) and 19 (37.3%) met relapse criteria for VMS severity and bother, respectively. Among the subgroup that had a higher than 20% reduction on all three VMS relapse parameters (frequency, severity, and bother) after 8 weeks of treatment (*n* = 49), 16.3% of participants met relapse criteria for all three VMS endpoints (frequency, severity, and bother), whereas 56.0% did not relapse for any VMS endpoint (Fig. 1). For the group that relapsed, the mean (SD) daily VMS frequency changed from 8.9 (4.2) at baseline to 9.6 (4.5) at 3 weeks after escitalopram cessation, and from 9.5 (4.5) to 4.4 (3.0) for those who did not relapse. This translates into a 15.0% mean increase (95% CI, 4.0% reduction to 34.1% increase) in VMS frequency at the end of the posttreatment



**FIG. 1.** Relapse in measures of hot flash frequency, severity, and bother at 11 weeks among participants who improved\* with 8 weeks of escitalopram treatment (*n* = 49). \*Sample is restricted to the subgroup of women who had at least a 20% reduction on all three VMS measures (frequency, severity, and bother).

phase relative to their pretreatment baseline for the group that relapsed. Similarly, the group that had VMS severity relapse had a mean increase in VMS severity of 10.7% (95% CI, 4.8% reduction to 26.3% increase), and those with VMS bother relapse had a mean reduction in VMS bother of 1.5% (95% CI, 10.6% reduction to 7.6% increase). Further analysis showed that VMS frequency, severity, and bother increased after treatment cessation by at least 50% of the benefit gained from baseline to week 8 in 61.8%, 47.4%, and 54.9% of women who had experienced at least a 20% improvement during the intervention, respectively.

The proportion of women who relapsed was similar when more stringent definitions of treatment response were used to define the subgroup in the analysis. For those who had at least a 33% reduction in VMS from baseline to the end of the 8-week treatment period, 28.8%, 37.3%, and 34.2% met criteria for VMS frequency, severity, and bother relapse, respectively. Results were consistent when the analysis was restricted to those who had experienced at least a 50% reduction in symptoms with escitalopram.

**Predictors of VMS frequency, severity, and bother relapse**

In univariate analysis (Table 2), the characteristics associated with relapse of VMS frequency were higher levels of insomnia symptoms at baseline (*P* = 0.01) and a weaker response to escitalopram therapy (*P* = 0.02). Both characteristics remained significant predictors of VMS frequency relapse in multivariable analyses. For every one-point difference in the ISI, there was an 11% higher odds of relapse (*P* = 0.02); those whose VMS responded less well to escitalopram on week 8 had more than threefold higher odds of relapse on week 11. Women who had insomnia at baseline (ISI score >7, indicating mild or greater levels of insomnia) were more likely to relapse than those without insomnia (43% vs 17%, *P* = 0.04).

**TABLE 2.** Univariate and multivariate predictors of relapse ( $\leq 20\%$  reduction) in hot flash frequency at 11 weeks relative to baseline ( $n = 76$ )

Variable	Univariate analyses		Multivariate analysis	
	OR (95% CI)	P	OR (95% CI)	P
Age (5-y increase)	1.08 (0.62-1.88)	0.78		
Race		0.07 <sup>a</sup>		
African American	1.00 (reference)			
White	2.69 (0.92-7.92)			
BMI (5 kg/m <sup>2</sup> increase)	1.17 (0.81-1.70)	0.39		
Smoking				
Never	1.00 (reference)			
Past	0.90 (0.30-2.72)			
Current	1.21 (0.33-4.38)			
Menopause status <sup>b</sup>				
Postmenopausal	1.00 (reference)	0.31		
Perimenopausal	0.52 (0.15-1.82)			
Years since the final menstrual period		0.74 <sup>c</sup>		
<1	1.00 (reference)			
1 to <3	1.58 (0.42-5.95)			
$\geq 3$	1.00 (0.26-3.93)			
Duration of hot flashes, y		0.78		
0-2	1.00 (reference)			
3-5	0.73 (0.21-2.48)			
$\geq 6$	1.10 (0.35-3.52)			
Hormone therapy use (ever)		0.35		
No	1.00 (reference)			
Yes	1.61 (0.59-4.38)			
Baseline hot flash frequency (one flash increase)	0.97 (0.86-1.08)	0.54		
Insomnia Severity Index score (one-point increase)	1.11 (1.02-1.20)	0.01	1.11 (1.02-1.20)	0.02
PHQ-9 depression score (one-point increase)	1.08 (0.92-1.26)	0.35		
GAD-7 anxiety score (one-point increase)	1.02 (0.87-1.19)	0.84		
Escitalopram dose escalated on week 4		0.28		
No	1.00 (reference)			
Yes	1.74 (0.64-4.71)			
Response to escitalopram on week 8		0.02		0.03
20% to <50% reduction	1.00 (reference)		1.00 (reference)	
$\geq 50\%$ reduction	0.30 (0.11-0.82)		0.32 (0.11-0.90)	

OR, odds ratio; BMI, body mass index; PHQ-9, nine-item Patient Health Questionnaire; GAD-7, seven-item Generalized Anxiety Disorder.

<sup>a</sup>P value from a contrast comparing African-American and white participants.

<sup>b</sup>P value from a contrast comparing postmenopausal and perimenopausal participants.

<sup>c</sup>P value from a contrast testing for any difference between participants with less than 1, 1 to less than 3, and 3 or more years since the final menstrual period (comparison does not include participants who had undergone hysterectomy or oophorectomy at baseline).

Results of univariate analyses to identify predictors of relapse in VMS severity showed that higher pretreatment levels of insomnia ( $P = 0.02$ ) and depressive symptoms ( $P = 0.04$ ) were associated with a greater likelihood of relapse (Table 3). However, neither remained a significant predictor of relapse in multivariable analyses.

Univariate analyses of relapse in VMS bother also showed that white women and those with higher pretreatment levels of insomnia were more likely to relapse ( $P = 0.008$  and  $P = 0.009$ , respectively; Table 4). However, in multivariable analyses, only race was a significant predictor, with white women showing a 4.3 times higher odds of relapsing compared with African-American women.

#### Withdrawal symptoms after cessation of escitalopram

At the end of the 3-week posttreatment phase, 35 (46.1%) of 76 participants in the VMS frequency relapse analysis reported experiencing at least 2 of the 17 prespecified SSRI/SNRI withdrawal symptoms. The most common withdrawal symptoms were excessive sweating, dizziness/lightheadedness, and unusual or vivid dreams, which occurred in 33%, 18%, and 14% of participants, respectively. The proportion

of women reporting at least two SSRI withdrawal symptoms 3 weeks after treatment cessation did not differ between those who did and those who did not experience VMS frequency relapse (50% vs 44%,  $P = 0.62$ ). Similarly, women reporting SSRI/SNRI withdrawal symptoms were not more likely to meet relapse criteria for VMS severity (55% vs 37%,  $P = 0.20$ ) or VMS bother (58% vs 41%,  $P = 0.23$ ).

## DISCUSSION

Among perimenopausal and postmenopausal women who had at least a 20% improvement in VMS in response to escitalopram, approximately one third experienced relapse of VMS to pretreatment symptom levels by 3 weeks after treatment cessation. Symptom relapse occurred regardless of whether relapse was defined by VMS frequency, VMS severity, or VMS bother. The likelihood of VMS relapse was similar when more stringent definitions of treatment response were used to define the analysis sample. Relapse in VMS frequency occurred more commonly in those with higher levels of pretreatment insomnia symptoms and in those who had a weaker response to escitalopram. Higher

**TABLE 3.** Univariate and multivariate predictors of relapse ( $\leq 20\%$  reduction) in hot flash severity at 11 weeks relative to baseline ( $n = 57$ )

Variable	Univariate analyses		Multivariate analysis	
	OR (95% CI)	P	OR (95% CI)	P
Age (5-y increase)	0.84 (0.42-1.67)	0.62		
Race		0.06 <sup>a</sup>		
African American	1.00 (reference)			
White	3.02 (0.94-9.71)			
BMI (5 kg/m <sup>2</sup> increase)	1.20 (0.81-1.79)	0.37		
Smoking		0.70		
Never	1.00 (reference)			
Past	0.99 (0.29-3.35)			
Current	0.53 (0.12-2.43)			
Menopause status <sup>b</sup>		0.95		
Postmenopausal	1.00 (reference)			
Perimenopausal	0.96 (0.26-3.49)			
Years since the final menstrual period		0.45 <sup>c</sup>		
<1	1.00 (reference)			
1 to <3	1.08 (0.24-4.79)			
$\geq 3$	2.52 (0.52-12.30)			
Duration of hot flashes, y		0.99		
0-2	1.00 (reference)			
3-5	1.05 (0.28-3.99)			
$\geq 6$	1.11 (0.31-4.03)			
Hormone therapy use (ever)		0.90		
No	1.00 (reference)			
Yes	1.08 (0.32-3.62)			
Baseline hot flash severity (one-point increase)	1.56 (0.46, 5.29)	0.48		
Insomnia Severity Index score (one-point increase)	1.11 (1.02-1.21)	0.02	1.09 (0.99-1.20)	0.07
PHQ-9 depression score (one-point increase)	1.23 (1.01-1.49)	0.04	1.15 (0.93-1.42)	0.19
GAD-7 anxiety score (one-point increase)	1.01 (0.86-1.20)	0.88		
Escitalopram dose escalated on week 4		0.70		
No	1.00 (reference)			
Yes	1.24 (0.42-3.68)			
Response to escitalopram on week 8		0.12		
20% to <50% reduction	1.00 (reference)			
$\geq 50\%$ reduction	0.36 (0.10-1.32)			

OR, odds ratio; BMI, body mass index; PHQ-9, nine-item Patient Health Questionnaire; GAD-7, seven-item Generalized Anxiety Disorder.

<sup>a</sup>P value from a contrast comparing African-American and white participants.

<sup>b</sup>P value from a contrast comparing postmenopausal and perimenopausal participants.

<sup>c</sup>P value from a contrast testing for any difference between participants with less than 1, 1 to less than 3, and 3 or more years since the final menstrual period (comparison does not include participants who had undergone hysterectomy or oophorectomy at baseline).

pretreatment levels of insomnia also significantly predicted relapse in VMS severity and bother, but only in univariate analyses. Race was associated only with relapse of VMS bother, with African-American women less likely to report bother after discontinuation of escitalopram. The likelihood of relapse was not associated with the presence of SSRI withdrawal symptoms.

Our results show that a significant proportion of women who discontinue escitalopram therapy for VMS lose the therapeutic benefit of short-term SSRI treatment soon after stopping treatment. These data suggest that a sizeable number of treatment responders lose the benefit rapidly when the medication is discontinued, although it is also noteworthy that more than half of our participants did not relapse in VMS frequency, severity, or bother during this period. Our results are consistent with previous studies showing that VMS recur rapidly after short-term treatment with the SNRI venlafaxine,<sup>11</sup> although the previous study did not report the proportion of women whose symptoms returned to pretreatment levels. Because our study was limited to a 3-week posttreatment phase, we do not know whether the likelihood of relapse would continue to increase with time off medication. Conversely, we do not know whether a

longer period of initial SSRI treatment would reduce or postpone the return of symptoms after stopping medication.

Our findings are consistent with previous studies indicating that VMS recur after treatment discontinuation in a significant proportion of women receiving HT treatment,<sup>3-6</sup> and that VMS occur rapidly after treatment is stopped.<sup>4</sup> Although the proportion of women who reported VMS recurrence after HT cessation was larger than what we observed in the present study,<sup>3-6</sup> our results cannot be compared directly to other studies because of differences in the treatments and duration of time after stopping medication. However, it is noteworthy that our study is the only one to assess the return of symptoms relative to baseline levels, rather than a global assessment of symptom recurrence.

These analyses highlight the importance of recognizing insomnia symptoms as a key factor associated with VMS relapse. Identifying women who report both VMS and insomnia before initiation of SSRI therapy and counseling them about possible relapse could be helpful. However, it is important to recognize that VMS may not be the only cause of insomnia in this population because stress, sleep apnea, depression, and common medical problems (eg, gastroesophageal reflux

**TABLE 4.** Univariate and multivariate predictors of relapse ( $\leq 20\%$  reduction) in hot flash bother at 11 weeks relative to baseline ( $n = 51$ )

Variable	Univariate analyses		Multivariate analysis	
	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Age (5-y increase)	1.26 (0.62-2.57)	0.53		
Race		0.008 <sup>a</sup>		0.04 <sup>a</sup>
African American	1.00 (reference)		1.00 (reference)	
White	6.14 (1.62-23.29)		4.31 (1.05-17.62)	
BMI (5 kg/m <sup>2</sup> increase)	1.15 (0.76-1.73)	0.52		
Smoking		0.24		
Never	1.00 (reference)			
Past	0.39 (0.01-1.54)			
Current	0.31 (0.05-1.76)			
Menopause status <sup>b</sup>		0.85		
Postmenopausal	1.00 (reference)			
Perimenopausal	0.88 (0.24-3.26)			
Years since the final menstrual period		0.57 <sup>c</sup>		
<1	1.00 (reference)			
1 to <3	1.43 (0.30-6.88)			
$\geq 3$	2.50 (0.46-13.65)			
Duration of hot flashes, y		0.92		
0-2	1.00 (reference)			
3-5	1.33 (0.34-5.27)			
$\geq 6$	1.11 (0.27-4.60)			
Hormone therapy use (ever)		0.61		
No	1.00 (reference)			
Yes	1.39 (0.40-4.86)			
Baseline hot flash bother (one-point increase)	0.55 (0.16-1.86)	0.33		
Insomnia Severity Index score (one-point increase)	1.15 (1.04-1.27)	0.009	1.11 (1.00-1.24)	0.06
PHQ-9 depression score (one-point increase)	1.19 (0.98-1.46)	0.08		
GAD-7 anxiety score (one-point increase)	0.98 (0.82-1.17)	0.84		
Escitalopram dose escalated on week 4		0.51		
No	1.00 (reference)			
Yes	0.68 (0.22-2.16)			
Response to escitalopram on week 8		0.54		
20% to <50% reduction	1.00 (reference)			
$\geq 50\%$ reduction	0.70 (0.22-2.19)			

OR, odds ratio; BMI, body mass index; PHQ-9, nine-item Patient Health Questionnaire; GAD-7, seven-item Generalized Anxiety Disorder.

<sup>a</sup>*P* value from a contrast comparing African-American and white participants.

<sup>b</sup>*P* value from a contrast comparing postmenopausal and perimenopausal participants.

<sup>c</sup>*P* value from a contrast testing for any difference between participants with less than 1, 1 to less than 3, and 3 or more years since the final menstrual period (comparison does not include participants who had undergone hysterectomy or oophorectomy at baseline).

disease, hypertension, and obesity) are also frequent causes of insomnia in a perimenopausal and postmenopausal population. These data raise the possibility that women with co-occurring VMS and insomnia symptoms may benefit from a longer duration of VMS therapy or from switching to insomnia treatments as part of an SSRI discontinuation plan.

African-American women are more likely to report VMS during perimenopause and postmenopause than are white women,<sup>12</sup> and they experience hot flashes for a longer duration.<sup>13</sup> It is therefore notable that although African Americans and whites did not differ in their VMS response to SSRI therapy,<sup>2</sup> African-American women were less likely to report bother after cessation of SSRI therapy. Additional studies are needed to better understand racial differences in response to treatments of VMS.

Women who did not respond well to escitalopram were more likely to experience relapse of VMS frequency. Conversely, a more robust response was protective against VMS relapse. The dose increase was not predictive of relapse, nor were withdrawal symptoms. Other characteristics not associated with relapse were age, menopause status, baseline VMS

symptom level, duration of VMS, years from final menstrual period, body mass index, or smoking status, all of which we hypothesized to be associated with relapse because they are predictive of VMS occurrence in this population.<sup>12</sup>

Women who had VMS relapse after SSRI discontinuation were not more likely to report SSRI withdrawal symptoms than those who did not relapse. This observation suggests that withdrawal symptoms did not influence the likelihood of relapse, nor were withdrawal symptoms of excessive sweating misinterpreted as VMS recurrence.

This study is the first to describe the likelihood of VMS relapse after discontinuation of nonhormonal treatments of VMS. The analysis is strengthened by the double-blinded discontinuation conditions because participants and staff were unaware of the treatment assignment during the 8-week trial and throughout the posttreatment phase. Limitations of our study include the brief 3-week period of posttreatment assessment after an 8-week treatment period and the modest sample of escitalopram-treated participants, which reduced our ability to assess whether baseline demographic, menopausal, or psychological characteristics (Tables 2-4) were predictors of VMS

relapse. In addition, the categorical definition of relapse may underestimate relapse among those who had a large response to SSRI therapy and a return of symptoms when medication was discontinued if their symptoms did not return to within 20% of baseline levels, as defined in this study. We cannot extrapolate our findings to other clinical settings in which SSRI treatment is continued for a longer period, nor do we know whether the likelihood of VMS relapse would continue to increase with time off treatment.

### CONCLUSIONS

In summary, our findings indicate that approximately one third of perimenopausal and postmenopausal women who discontinue escitalopram therapy shortly after they improve report a swift return of VMS. White women and those with higher levels of pretreatment insomnia symptoms are more likely to experience symptom relapse. VMS relapse is not associated with SSRI withdrawal symptoms or other menopause characteristics in this sample. These data have important clinical implications for women with VMS who respond to SSRI treatment. Counseling women about the likelihood of relapse when medication is discontinued and the risks and benefits of treatment continuation is an important consideration. Based on our findings, women should be informed that the therapeutic effect of SSRI may be limited to the duration of time that the SSRI is taken, similar to what has been observed with estrogen therapy. In addition, because women who are white, have more insomnia symptoms, or have a less robust response to the treatment seem more likely to relapse after treatment discontinuation, they may benefit from a longer period of treatment. Future studies will examine whether such strategies can reduce the likelihood of VMS relapse when medication is discontinued.

### REFERENCES

1. Loprinzi CL, Diekmann B, Novotny PJ, Stearns V, Sloan JA. Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration. *Menopause* 2009;16:184-187.
2. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. *JAMA* 2011;305:267-274.
3. Lindh-Astrand L, Brynhildsen J, Hoffman M, Hammar M. Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy: a Swedish population-based study. *Menopause* 2009;16:1213-1217.
4. Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. *Obstet Gynecol* 2003;102:1233-1239.
5. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. *JAMA* 2005;294:183-193.
6. Brunner RL, Aragaki A, Barnabei V, et al. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. *Menopause* 2010;17:946-954.
7. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. *Br J Psychiatry* 2000;176:363-368.
8. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. *Sleep Med* 2001;2:297-307.
9. Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. *J Gen Intern Med* 2007;22:1596-1602.
10. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166:1092-1097.
11. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. *J Clin Oncol* 2010;28:5147-5152.
12. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. *Am J Public Health* 2006;96:1226-1235.
13. Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR. Duration of menopausal hot flushes and associated risk factors. *Obstet Gynecol* 2011;117:1095-1104.